Wall Street analyst consensus ratings for Autolus Therapeutics (NASDAQ: AUTL) lean strongly toward a Strong Buy, with a vast majority of tracking firms recommending a Buy or Strong Buy rating and no active sell recommendations. Analysts emphasize its promising clinical pipeline and commercialization execution, balanced against early-stage biotechnology cash-burn risks.